Diabetes and skeletal health

Area of Science:

• Endocrinology
• Metabolic Diseases
• Bone Biology

Background:

• Diabetes mellitus and osteoporosis are prevalent in aging populations.
• Individuals with diabetes exhibit an elevated risk of fractures, leading to increased morbidity and mortality.
• Both Type 1 and Type 2 diabetes are linked to impaired bone health, affecting bone mass and quality.

Purpose of the Study:

• To investigate the relationship between diabetes, osteoporosis, and fracture risk.
• To explore the mechanisms by which diabetes impacts bone metabolism.
• To examine the specific effects of thiazolidinediones (TZDs) on bone health in diabetic patients.

Main Methods:

• Review of existing literature on diabetes, osteoporosis, and fracture incidence.
• Analysis of studies examining bone mineral density and bone turnover markers in diabetic individuals.
• Investigation of the molecular pathways, including insulin signaling, advanced glycation end products, and calcium homeostasis, affected by diabetes.
• Evaluation of the impact of thiazolidinediones (rosiglitazone and pioglitazone) on osteoblast and adipocyte differentiation.

Main Results:

• Diabetes is associated with a higher risk of fractures, particularly hip fractures.
• Type 1 diabetes shows decreased bone mass, while Type 2 diabetes presents altered bone quality.
• Mechanisms include altered insulin, IGF-1, cytokine, and calcium homeostasis.
• Thiazolidinediones (TZDs) promote adipogenesis and inhibit osteoblastogenesis by activating PPARγ2.
• TZD use is linked to increased fracture risk, reduced bone mineral density, and altered bone turnover markers.

Conclusions:

• Diabetes significantly increases fracture risk due to complex metabolic and cellular alterations.
• Thiazolidinediones (TZDs) pose an additional risk for fractures by disrupting bone cell differentiation pathways.
• Further research is needed to mitigate fracture risk in diabetic patients, especially those on TZD therapy.